Clinical response, drug survival and predictors thereof in 432 ankylosing spondylitis patients after switching tumour necrosis factor α inhibitor therapy: results from the Danish nationwide DANBIO registry

Bente Glintborg; Mikkel Østergaard; Niels Steen Krogh; Ulrik Tarp; Natalia Manilo; Anne Gitte Rasmussen Loft; Annette Hansen; Annette Schlemmer; Victoria Fana; Hanne M. Lindegaard; Henrik Nordin; Claus Rasmussen; Leif Ejstrup; Dorte Vendelbo Jensen; Peter Mosborg Petersen; Merete Lund Hetland

doi:10.1136/annrheumdis-2012-201933

Clinical response, drug survival and predictors thereof in 432 ankylosing spondylitis patients after switching tumour necrosis factor α inhibitor therapy: results from the Danish nationwide DANBIO registry

Bente Glintborg, Mikkel Østergaard, Niels Steen Krogh, Ulrik Tarp, Natalia Manilo, Anne Gitte Rasmussen Loft, Annette Hansen, Annette Schlemmer, Victoria Fana, Hanne M. Lindegaard, Henrik Nordin, Claus Rasmussen, Leif Ejstrup, Dorte Vendelbo Jensen, Peter Mosborg Petersen, Merete Lund Hetland

87 Citations (Scopus)

Abstract

OBJECTIVE: To investigate frequencies and reasons for switching, treatment responses and drug survival in patients with ankylosing spondylitis (AS) switching tumour-necrosis-factor-α inhibitor (TNFi) treatment in routine clinical care. METHODS: AS patients were identified in the Danish nationwide DANBIO registry. Disease activity, treatment responses (50% or 20 mm reduction in Bath AS Disease Activity Index (BASDAI)), duration and rates of drug survival and predictors thereof were studied in patients receiving ≥2 different biological drugs. RESULTS: Of 1436 AS patients starting TNFi treatment, 432 patients (30%) switched to a second and 137 (10%) to a third biological drug. Compared with non-switchers, switchers were more frequently women (33%/22%), had shorter disease duration (3 years/5 years) and higher BASDAI (62(52-76) mm/56(43-69) mm (median(interquartile-range))), Bath AS Functional Index (BASFI) (54(39-71) mm/47(31-65) mm) and visual-analogue-scale (VAS) global, pain and fatigue scores when they started the first TNFi (all p

Original language	English
Journal	Annals of the Rheumatic Diseases
ISSN	0003-4967
DOIs	https://doi.org/10.1136/annrheumdis-2012-201933
Publication status	Published - Jul 2013

Access to Document

10.1136/annrheumdis-2012-201933

Fingerprint

Dive into the research topics of 'Clinical response, drug survival and predictors thereof in 432 ankylosing spondylitis patients after switching tumour necrosis factor α inhibitor therapy: results from the Danish nationwide DANBIO registry'. Together they form a unique fingerprint.

Cite this

Glintborg, B., Østergaard, M., Krogh, N. S., Tarp, U., Manilo, N., Loft, A. G. R., Hansen, A., Schlemmer, A., Fana, V., Lindegaard, H. M., Nordin, H., Rasmussen, C., Ejstrup, L., Jensen, D. V., Petersen, P. M., & Hetland, M. L. (2013). Clinical response, drug survival and predictors thereof in 432 ankylosing spondylitis patients after switching tumour necrosis factor α inhibitor therapy: results from the Danish nationwide DANBIO registry. Annals of the Rheumatic Diseases. https://doi.org/10.1136/annrheumdis-2012-201933

Clinical response, drug survival and predictors thereof in 432 ankylosing spondylitis patients after switching tumour necrosis factor α inhibitor therapy : results from the Danish nationwide DANBIO registry. / Glintborg, Bente; Østergaard, Mikkel; Krogh, Niels Steen et al.

In: Annals of the Rheumatic Diseases, 07.2013.

Research output: Contribution to journal › Journal article › Research › peer-review

Glintborg, B, Østergaard, M, Krogh, NS, Tarp, U, Manilo, N, Loft, AGR, Hansen, A, Schlemmer, A, Fana, V, Lindegaard, HM, Nordin, H, Rasmussen, C, Ejstrup, L, Jensen, DV, Petersen, PM & Hetland, ML 2013, 'Clinical response, drug survival and predictors thereof in 432 ankylosing spondylitis patients after switching tumour necrosis factor α inhibitor therapy: results from the Danish nationwide DANBIO registry', Annals of the Rheumatic Diseases. https://doi.org/10.1136/annrheumdis-2012-201933

@article{51e32b40f9d74cb4b2f17858d313cee1,

title = "Clinical response, drug survival and predictors thereof in 432 ankylosing spondylitis patients after switching tumour necrosis factor α inhibitor therapy: results from the Danish nationwide DANBIO registry",

abstract = "OBJECTIVE: To investigate frequencies and reasons for switching, treatment responses and drug survival in patients with ankylosing spondylitis (AS) switching tumour-necrosis-factor-α inhibitor (TNFi) treatment in routine clinical care. METHODS: AS patients were identified in the Danish nationwide DANBIO registry. Disease activity, treatment responses (50% or 20 mm reduction in Bath AS Disease Activity Index (BASDAI)), duration and rates of drug survival and predictors thereof were studied in patients receiving ≥2 different biological drugs. RESULTS: Of 1436 AS patients starting TNFi treatment, 432 patients (30%) switched to a second and 137 (10%) to a third biological drug. Compared with non-switchers, switchers were more frequently women (33%/22%), had shorter disease duration (3 years/5 years) and higher BASDAI (62(52-76) mm/56(43-69) mm (median(interquartile-range))), Bath AS Functional Index (BASFI) (54(39-71) mm/47(31-65) mm) and visual-analogue-scale (VAS) global, pain and fatigue scores when they started the first TNFi (all p",

author = "Bente Glintborg and Mikkel {\O}stergaard and Krogh, {Niels Steen} and Ulrik Tarp and Natalia Manilo and Loft, {Anne Gitte Rasmussen} and Annette Hansen and Annette Schlemmer and Victoria Fana and Lindegaard, {Hanne M.} and Henrik Nordin and Claus Rasmussen and Leif Ejstrup and Jensen, {Dorte Vendelbo} and Petersen, {Peter Mosborg} and Hetland, {Merete Lund}",

year = "2013",

month = jul,

doi = "10.1136/annrheumdis-2012-201933",

language = "English",

journal = "Annals of the Rheumatic Diseases",

issn = "0003-4967",

publisher = "B M J Group",

}

TY - JOUR

T1 - Clinical response, drug survival and predictors thereof in 432 ankylosing spondylitis patients after switching tumour necrosis factor α inhibitor therapy

T2 - results from the Danish nationwide DANBIO registry

AU - Glintborg, Bente

AU - Østergaard, Mikkel

AU - Krogh, Niels Steen

AU - Tarp, Ulrik

AU - Manilo, Natalia

AU - Loft, Anne Gitte Rasmussen

AU - Hansen, Annette

AU - Schlemmer, Annette

AU - Fana, Victoria

AU - Lindegaard, Hanne M.

AU - Nordin, Henrik

AU - Rasmussen, Claus

AU - Ejstrup, Leif

AU - Jensen, Dorte Vendelbo

AU - Petersen, Peter Mosborg

AU - Hetland, Merete Lund

PY - 2013/7

Y1 - 2013/7

N2 - OBJECTIVE: To investigate frequencies and reasons for switching, treatment responses and drug survival in patients with ankylosing spondylitis (AS) switching tumour-necrosis-factor-α inhibitor (TNFi) treatment in routine clinical care. METHODS: AS patients were identified in the Danish nationwide DANBIO registry. Disease activity, treatment responses (50% or 20 mm reduction in Bath AS Disease Activity Index (BASDAI)), duration and rates of drug survival and predictors thereof were studied in patients receiving ≥2 different biological drugs. RESULTS: Of 1436 AS patients starting TNFi treatment, 432 patients (30%) switched to a second and 137 (10%) to a third biological drug. Compared with non-switchers, switchers were more frequently women (33%/22%), had shorter disease duration (3 years/5 years) and higher BASDAI (62(52-76) mm/56(43-69) mm (median(interquartile-range))), Bath AS Functional Index (BASFI) (54(39-71) mm/47(31-65) mm) and visual-analogue-scale (VAS) global, pain and fatigue scores when they started the first TNFi (all p

AB - OBJECTIVE: To investigate frequencies and reasons for switching, treatment responses and drug survival in patients with ankylosing spondylitis (AS) switching tumour-necrosis-factor-α inhibitor (TNFi) treatment in routine clinical care. METHODS: AS patients were identified in the Danish nationwide DANBIO registry. Disease activity, treatment responses (50% or 20 mm reduction in Bath AS Disease Activity Index (BASDAI)), duration and rates of drug survival and predictors thereof were studied in patients receiving ≥2 different biological drugs. RESULTS: Of 1436 AS patients starting TNFi treatment, 432 patients (30%) switched to a second and 137 (10%) to a third biological drug. Compared with non-switchers, switchers were more frequently women (33%/22%), had shorter disease duration (3 years/5 years) and higher BASDAI (62(52-76) mm/56(43-69) mm (median(interquartile-range))), Bath AS Functional Index (BASFI) (54(39-71) mm/47(31-65) mm) and visual-analogue-scale (VAS) global, pain and fatigue scores when they started the first TNFi (all p

U2 - 10.1136/annrheumdis-2012-201933

DO - 10.1136/annrheumdis-2012-201933

M3 - Journal article

C2 - 22941767

SN - 0003-4967

JO - Annals of the Rheumatic Diseases

JF - Annals of the Rheumatic Diseases

ER -